PDF(Pubmed)
Abstract：
Osteonecrosis is a debilitating condition characterized by the loss of blood supply to the bones, leading to bone death. This condition can impact various bones, including the jaw, which significantly affects patients\' quality of life by causing difficulties in swallowing, feeding, chewing, and speaking, along with swollen, painful mucous membranes and chronic sinusitis. Osteonecrosis can arise due to treatment with antiresorptive drugs. However, there is a growing number of reports of osteonecrosis following novel targeted anti-cancer treatments, such as tyrosine kinase inhibitors (TKIs) and biological therapies. The pathogenesis of osteonecrosis is linked to the side effects of the antiangiogenic mechanisms of these medications, leading to a disrupted blood flow. Our review aims to examine recent insights into osteonecrosis triggered by new anti-cancer drugs. Most reports focus on the osteonecrosis of the jaw (ONJ); however, we discovered that some authors have described cases of osteonecrosis affecting the femoral head or elbow following novel anti-cancer treatments. Prevention is a key component in managing osteonecrosis. Therefore, a comprehensive risk assessment should always be performed before and during anti-cancer therapy.
摘要：
骨坏死是一种衰弱的疾病，其特征是骨骼的血液供应丧失，导致骨头死亡。这种情况会影响各种骨骼，包括下巴,通过导致吞咽困难显著影响患者的生活质量，喂养,咀嚼,说话,随着肿胀，粘膜疼痛和慢性鼻窦炎。由于用抗吸收药物治疗，可能会出现骨坏死。然而,有越来越多的骨坏死的报道后，新的靶向抗癌治疗，例如酪氨酸激酶抑制剂(TKIs)和生物疗法。骨坏死的发病机制与这些药物的抗血管生成机制的副作用有关，导致血流中断.我们的综述旨在研究新的抗癌药物引发的骨坏死的最新见解。大多数报告集中在颌骨坏死（ONJ）;然而，我们发现，一些作者描述了在新型抗癌治疗后影响股骨头或肘部的骨坏死病例。预防是治疗骨坏死的关键组成部分。因此,在抗癌治疗之前和期间,应始终进行全面的风险评估.
